Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• PVG Asset Management, owning 0.36% of shares, is soliciting proxies to replace the entire board with six new nominees at the 2026 annual meeting, citing poor governance, lack of transparency, and strategic missteps.

• The solicitation follows significant management turnover, regulatory non-compliance, and missed SEC filings, resulting in a Nasdaq delinquency notice and depressed stock price.

• PVG criticizes the current board for insufficient industry expertise, lack of accountability, and failure to advance key clinical programs, particularly for Alzheimer's drug blarcamesine.

• PVG proposes a new board with deep biotech, investment, and operational experience, aiming to restore compliance, accelerate clinical development, and improve investor relations.

• The annual meeting will be held virtually on September 24, 2026, with voting via a universal proxy card.

Voting matters and shareholder proposals

• Proposal 1: Elect six PVG nominees to the board, replacing up to six incumbent directors.

• Proposal 2: Ratify Grant Thornton LLP as independent auditor for FY ending September 30, 2026; PVG makes no recommendation but will vote FOR.

• Shareholders may vote for any combination of nominees using the GOLD universal proxy card; voting for more than six invalidates the ballot.

• Procedures for submitting shareholder proposals and director nominations for the 2027 meeting are outlined, with deadlines and requirements specified.

Board of directors and corporate governance

• PVG criticizes the current board for lack of biotech expertise, minimal stock ownership, and poor oversight.

• PVG's nominees have backgrounds in biotech investment, clinical development, and capital markets.

• PVG pledges to require board members and key employees to purchase stock, emphasizing alignment with shareholders.

• If elected, PVG plans to hire an experienced CEO and CMO with CNS drug development track records.